# The Effect of Early Administration of PCSK9 Inhibitor to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile

Study · id `cardio:ct-nct06083961` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06083961](<https://clinicaltrials.gov/study/NCT06083961>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06083961

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT06083961. Non-randomized; no masking; primary purpose treatment. Start 2023-10-15 (anticipated); primary completion 2026-10-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT06083961, source copy `cardio:ctgov-nct06083961-2023-10-16`, retrieved 2026-11-18)
- Planned start: 2023-10-15 (anticipated) (ClinicalTrials.gov record NCT06083961, source copy `cardio:ctgov-nct06083961-2023-10-16`, retrieved 2026-11-18)
- Primary completion: 2026-10-15 (anticipated) (ClinicalTrials.gov record NCT06083961, source copy `cardio:ctgov-nct06083961-2023-10-16`, retrieved 2026-11-18)
- Completion: 2026-11-15 (anticipated) (ClinicalTrials.gov record NCT06083961, source copy `cardio:ctgov-nct06083961-2023-10-16`, retrieved 2026-11-18)
- Countries: South Korea (ClinicalTrials.gov record NCT06083961, source copy `cardio:ctgov-nct06083961-2023-10-16`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06083961-2023-10-16`, retrieved 2026-11-18)

## The registry's words

- Brief title: The Effect of Early Administration of PCSK9 Inhibitor to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile
- Condition: Stroke, Acute Ischemic
- Condition: PCSK9 Inhibitor
- Intervention (Drug): Alirocumab
- Lead sponsor: Sun U. Kwon
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Alirocumab (`cardio:alirocumab`)

## Provenance

Content hash: 81044cff7fba0429d6c6c6abb72553cb51317e70c1fe25f831ee5eaa06f0312d
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
